CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $90.21M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
66.80MGBP90.21M · vs all stocks (USD)
Revenue (TTM)
225.00KGBP303.87K · vs all stocks (USD)
52-Week Change
0.92%vs all stocks
Market Capitalization
66.80MGBP90.21M · vs all stocks (USD)
Enterprise Value
8.04MGBP10.86M · vs all stocks (USD)
Forward P/E
-10.90xvs Medical Devices peers
Price to Book (MRQ)
2.23xvs Medical Devices peers
Enterprise to Revenue
35.73xvs Medical Devices peers
Enterprise to EBITDA
-0.8060xvs Medical Devices peers
Operating Margin
-4571.30%vs Medical Devices peers
Return on Assets (TTM)
-49.94%vs Medical Devices peers
Return on Equity (TTM)
-76.51%vs Medical Devices peers
Revenue (TTM)
225.00KGBP303.87K · vs all stocks (USD)
Revenue per Share (TTM)
0.0030GBPUpdated Jul 28, 2026Gross Profit (TTM)
225.00KGBP303.87K · vs all stocks (USD)
EBITDA (TTM)
-9.98MGBP-13.47M · vs all stocks (USD)
Net Income (TTM)
-8.41MGBP-11.36M · vs all stocks (USD)
Operating Cash Flow (TTM)
-7.00MGBP-9.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-6.88MGBP-9.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
4.00MGBPFY2024 · Dec 31, 2024Cost of Goods Sold
2.10MGBPFY2024 · Dec 31, 2024Gross Profit
1.90MGBPFY2024 · Dec 31, 2024Operating Income
-28.80MGBP-38.90M · vs all stocks (USD)
Pre-tax Income
-29.00MGBPFY2024 · Dec 31, 2024Income Tax Expense
-1.20MGBPFY2024 · Dec 31, 2024Net Income
-28.70MGBPFY2024 · Dec 31, 2024EBIT
-28.60MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-26.10MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
30.30MGBPFY2024 · Dec 31, 2024Non-operating Interest Income
200.00KGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
400.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0800GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0800GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
369.98MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
369.98MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-27.80MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-27.00MGBPFY2024 · Dec 31, 2024Free Cash Flow
-27.30MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
12.30MGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-27.80MGBPFY2024 · Dec 31, 2024Stock-based Compensation
1.50MGBPFY2024 · Dec 31, 2024Other Non-cash Items
-400.00KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-1.00MGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
700.00KGBPFY2024 · Dec 31, 2024Capital Expenditures
-300.00KGBPFY2024 · Dec 31, 2024Net Intangibles (CF)
-100.00KGBPFY2024 · Dec 31, 2024Net Acquisitions
0.00GBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-300.00KGBPFY2024 · Dec 31, 2024Long-term Debt Issuance
6.40MGBPFY2024 · Dec 31, 2024Long-term Debt Payments
-600.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
16.90MGBPFY2024 · Dec 31, 2024Shares Outstanding
412.47MSharesUpdated Jul 28, 2026Float Shares
85.07MSharesUpdated Jul 28, 2026% Held by Insiders
7.41%vs all stocks
% Held by Institutions
40.54%vs all stocks
Total Cash (MRQ)
12.40MGBP16.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1030GBPUpdated Jul 28, 2026Total Debt (MRQ)
4.10MGBP5.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0820xvs Medical Devices peers
Current Ratio (MRQ)
4.65xvs Medical Devices peers
Book Value per Share (MRQ)
0.0610GBPUpdated Jul 28, 2026Total Assets
65.00MGBP87.78M · vs all stocks (USD)
Total Current Assets
56.40MGBPFY2024 · Dec 31, 2024Total Liabilities
22.60MGBPFY2024 · Dec 31, 2024Total Non-current Assets
8.60MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
2.10MGBPFY2024 · Dec 31, 2024Total Current Liabilities
20.50MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
8.70MGBPFY2024 · Dec 31, 2024Accounts Receivable
900.00KGBPFY2024 · Dec 31, 2024Inventory
2.70MGBPFY2024 · Dec 31, 2024Accounts Payable
900.00KGBPFY2024 · Dec 31, 2024Short-term Debt
2.40MGBPFY2024 · Dec 31, 2024Long-term Debt
2.00MGBPFY2024 · Dec 31, 2024Common Stock (Book)
400.00KGBPFY2024 · Dec 31, 2024Retained Earnings
-173.10MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
42.40MGBP57.26M · vs all stocks (USD)
52-Week Low
9.52GBXUpdated Jul 28, 202652-Week High
18.50GBXUpdated Jul 28, 202652-Week Change
0.92%vs all stocks
50-Day MA
13.78GBXUpdated Jul 28, 2026200-Day MA
12.59GBXUpdated Jul 28, 2026Avg 10-Day Volume
600.94KSharesUpdated Jul 28, 2026Avg 30-Day Volume
666.55KSharesUpdated Jul 28, 2026Diluted EPS (TTM)
-0.0400GBPUpdated Jul 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $90.21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 90,213,262.005Global P5: 279,010,173.859
Revenue is $303,869, lower than 95% of all stocks globallySignificant
Revenue (USD): 303,869.25Global P5: 32,166,921.735
Companies that share the same coordination system — how they create, deliver, or capture value.
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tenax Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule